Serious spike in market valuation ahead if If TLD1433 delivers on both oncology (pivotal NMIBC Ph. 2) and vaccine (enveloped viruses like COVID-19, influenza, Zika, herpes simplex, MonkeyPox, shingle, etc ...), and that we are granted FDA Breakthrough designation and Accelerated Approval (that would allow us to receive revenues from the remaining patients enrolling in our Ph. 2), then we land on the radar of big pharmas, without any doubt.
For sure, the credibility of NML will de facto capture the interest of big pharmas as it will be a validation from a 3rd party that has worldwide expertise and knowhow.
And regarding the NMIBC indication, our 2 main competitors are combos and they require many treatments.
We would get credibility on both markets! You rarely see that.